Replies to post #26191 on Marker Therapeutics Inc (MRKR)

[Phantom Lord]

I'm pretty irritated. This seems like a fairly large oversight on BCM's and Marker's part assuming Marker did get to review the abstract before it was submitted. From the conference call it sounded like they were pretty confident it would be accepted. The Janney research report also listed potential pancreatic data at ASCO as a potential upcoming event. I definitely didn't see this coming. That being said we don't have all the information as to why it wasn't accepted or why we now have to wait until Q3 to see any of the initial data. I doubt there will be a PR but who really knows.

I'm in the process of setting up a call with Peter. Shooting for later today and hopefully I can get a little clarification. The 8K was too vague to draw any conclusions from.

EDIT: Call is at 1:00 central.